title: [Radioisotope therapy with somatostatin analogues in neuroendocrine tumours (case report)].
abstract: Restricted number of neuroendocrine tumors (NET) shows overexpression of somatostatin receptors. Therefore, long-acting somatostatin analogues are used in diagnosis and treatment of those tumors. Here we present our first case of NET, localized in pancreas treated with DOTA-D-Phe 1-Tyr 3-octreotide (DOTATATE), for receptor-mediated radioisotope therapy. DOTATATE is a newly developed somatostatin analogue labeled with beta-emitter yttrium 90 (90Y) and beta, gamma-emitter lutetium 177 (177Lu). A 34-year old woman was suffering from several years gastrointestinal symptoms. NET of the pancreas with multiple metastases into the liver was diagnosed based on histopatological, biochemical and radiological tests. First, she had chemiotherapy (leucovorin, 5-FU, cisplatin), however there was any positive effects of this therapy. Next, she received four single doses of 90Y DOTATATE at 4-6- week intervals, yielding a cumulative dose of 7.4 GBq/m2. During the 4th cycle the Lu-177 DOTATATE was additionally administered. As a renal protection i.v. infusion of amino acid solution were used during the treatment sessions. To date, patient has shown partial remission with reduction of tumor masses. We observed spectacular clinical, biochemical and radiological improvement. Radioisotope therapy could be a powerful and promising method of treatment at least in patients who had no other treatment option.
authors.affiliation: Department of Nuclear Medicine, Medical University, Warsaw.
authors.forename: Jolanta
authors.initials: J
authors.lastname: Kunikowska
authors.forename: Leszek
authors.initials: L
authors.lastname: Królicki
authors.forename: Jarosław
authors.initials: J
authors.lastname: Cwikła
authors.forename: Renata
authors.initials: R
authors.lastname: Mikołajczak
authors.forename: Dariusz
authors.initials: D
authors.lastname: Pawlak
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Korsak
authors.forename: Izabela
authors.initials: I
authors.lastname: Kozłowicz
authors.forename: Jakub
authors.initials: J
authors.lastname: Poprawski
authors.forename: Maria
authors.initials: M
authors.lastname: Płazińska
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Kobylecka
authors.forename: Joanna
authors.initials: J
authors.lastname: Maczewska
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Zycińska
authors.forename: Kazimierz
authors.initials: K
authors.lastname: Wardyn
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D018358:Neuroendocrine Tumors / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary; D015282:Octreotide / Q000008:administration & dosage / Q000031:analogs & derivatives*; D009942:Organometallic Compounds / Q000008:administration & dosage*; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D019275:Radiopharmaceuticals / Q000008:administration & dosage*; D012074:Remission Induction; D013004:Somatostatin / Q000031:analogs & derivatives*
chemical_list: D007205:Indium Radioisotopes; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C121107:octreotide, DOTA-Tyr(3)-; D013004:Somatostatin; C447941:lutetium Lu 177 dotatate; D015282:Octreotide